Testbed 2: Engineered Immune Cells

In Year 6 we expanded the engineered T cell Test-Bed to other immune cells to recognize the emergence of other cellular immunotherapies including NK cells, B cells, macrophages, etc. Test-Bed 2 projects span the entire engineered system, from patient cell procurement to product distribution and delivery. The testbed has been expanded to include engineering and characterization natural killer cells through virus-free payloads. We have also built supply chain models of CAR T cell therapeutics considering real-time patient health status for prioritization of queuing and resource allocation, providing a much-needed platform for ethicists and cell manufacturing stakeholders to test decision-making scenarios.  Specific projects can be found below:

Projects

•    In-line Multi-omics to Establish Feedback Control within Immune Cell Bioreactor (Thrusts 2,3)

•    Patient-specific potency chips to assess T cell quality (Thrusts 1,2,3)

•    Scalable manufacturing of gene-modified primary natural killer cell therapies (Thrusts 1,2,3)

•    Development of Novel Supply Chain and Process Modeling Algorithms, Methods, and Tools for Cell Therapy Manufacturing and Distribution (Thrust 1)

Project Descriptions
 

  • Test-Bed 2: Patient-specific potency chips to assess T cell quality (Thrusts Involved: All)
  • Test-Bed 2: In-line Multi-omics to Establish Feedback Control within Immune Cell Bioreactor (Thrust Involved: 3)
  • Test-Bed 2: Development of Novel Supply Chain and Process Modeling Algorithms, Methods, and Tools for Cell Therapy Manufacturing and Distribution (Thrust Involved: 1)
  • Test-Bed 2: Label-free isolation of T lymphocytes from leukapheresis products with ultrahigh throughput and resolution (Thrust Involved: 2)
  • Test-Bed 2: Scalable Nanowires to Engineer CAR-T cells and Modulate T Cell Fitness (Thrust Involved: 3)
  • Test-Bed 2: Liquid Crystal Droplet-Based Biosensors for Cell Manufacturing Processes (Thrust Involved: 2)
  • Test-Bed 2: Hyper Redundant Flexible Manipulator (HRFM) “Snake Robot” (Thrust Involved: 3)
  • Test-Bed 2: Developing microfluidic devices to generate gene-edited nonactivated CAR T cells (Thrust Involved: 1)